Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493076 | 0.83 | TP53 (0.73) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2495532 | 0.81 | TP53 (0.70) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2495408 | 0.79 | TP53 (0.67) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13331736 | 0.79 | TP53 (0.67) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14837427 | 0.79 | TP53 (0.67) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3206483 | 0.79 | LMNA (0.63) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3199285 | 0.79 | LMNA (0.66) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL14837419 | 0.79 | TP53 (0.65) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3205551 | 0.78 | LMNA (0.67) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13621752 | 0.78 | LMNA (0.74) | TP53LMNANPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035951-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2010-02-11 | — | — | US | claimed |
| US-20100035951-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035951-A1 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN2, KCNN1, KCNN3 | TP53 4533/4885LMNA 2392/4885NPSR1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.